Credent Connect N Care, a healthcare logistics company, has raised Rs 26.53 crore from 10 anchor investors ahead of its initial public offering (IPO). Abakkus Asset Management, founded by noted investor Sunil Singhania, emerged as the largest participant among the anchor investors.

The company's Rs 93.90-crore IPO opened on August 13 and will remain available for subscription until August 17. The issue carries a price band of Rs 179–189 per share.

Anchor Investor Participation

Anchor investment is a standard mechanism in Indian IPOs wherein institutional investors are allotted shares a day before the public offering opens. This process helps establish demand and provides price discovery signals for retail investors. The participation of well-known asset management firms such as Abakkus is often seen as an indicator of institutional interest in the offering.

Sunil Singhania, founder of Abakkus Asset Management, previously served as head of equity at Aditya Birla Sun Life Mutual Fund and is widely recognized in Indian markets for his small- and mid-cap investment strategies. Ashish Kacholia, another prominent name in India's small-cap investing landscape, is known for identifying early-stage growth opportunities. Both Kacholia and Abakkus already held pre-IPO stakes in Credent Connect N Care, indicating existing investor relationships prior to the public issue.

Company Overview

Credent Connect N Care operates in the healthcare logistics sector, with the company working toward building a nationwide healthcare logistics network. Healthcare logistics involves the storage, transportation, and distribution of pharmaceutical products, medical devices, and other healthcare-related goods, ensuring that temperature-sensitive and time-critical medical supplies reach their destinations safely and efficiently.

The healthcare logistics industry in India has seen increased attention in recent years, driven by the expansion of pharmaceutical manufacturing, growth in diagnostic services, and the government's push to strengthen healthcare infrastructure across the country. India is among the world's largest producers of pharmaceuticals by volume, and the cold-chain logistics requirements for vaccines, biologics, and specialty drugs have created demand for specialized supply-chain operators. The IPO size of under Rs 100 crore places this offering in the SME (small and medium enterprise) segment, a category of Indian public listings that has drawn sustained investor participation through 2023 and 2024.

IPO Details and Financial Performance

The IPO size stands at Rs 93.90 crore, with shares offered in the price range of Rs 179–189. The subscription window runs from August 13 through August 17. Further details regarding the company's financial performance and the specific breakdown of the fresh issue versus any offer-for-sale component were referenced in the original report.

Source: Economic Times Markets